- Home
- CNSP vs GLTO Comparison
CNSP vs GLTO Comparison
Compare CNSP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- GLTO
- Stock Information
- Founded
- CNSP 2017
- GLTO 2011
- Country
- CNSP United States
- GLTO Denmark
- Employees
- CNSP N/A
- GLTO N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- GLTO Health Care
- Exchange
- CNSP Nasdaq
- GLTO Nasdaq
- Market Cap
- CNSP 4.0M
- GLTO 4.5M
- IPO Year
- CNSP 2019
- GLTO 2020
- Fundamental
- Price
- CNSP $6.19
- GLTO $3.01
- Analyst Decision
- CNSP Hold
- GLTO Buy
- Analyst Count
- CNSP 1
- GLTO 1
- Target Price
- CNSP N/A
- GLTO $10.00
- AVG Volume (30 Days)
- CNSP 79.4K
- GLTO 8.2K
- Earning Date
- CNSP 08-14-2025
- GLTO 10-31-2025
- Dividend Yield
- CNSP N/A
- GLTO N/A
- EPS Growth
- CNSP N/A
- GLTO N/A
- EPS
- CNSP N/A
- GLTO N/A
- Revenue
- CNSP N/A
- GLTO N/A
- Revenue This Year
- CNSP N/A
- GLTO N/A
- Revenue Next Year
- CNSP N/A
- GLTO N/A
- P/E Ratio
- CNSP N/A
- GLTO N/A
- Revenue Growth
- CNSP N/A
- GLTO N/A
- 52 Week Low
- CNSP $4.93
- GLTO $2.01
- 52 Week High
- CNSP $221.94
- GLTO $14.82
- Technical
- Relative Strength Index (RSI)
- CNSP 42.48
- GLTO 33.12
- Support Level
- CNSP $5.85
- GLTO $2.95
- Resistance Level
- CNSP $6.37
- GLTO $3.28
- Average True Range (ATR)
- CNSP 0.68
- GLTO 0.12
- MACD
- CNSP 0.13
- GLTO -0.04
- Stochastic Oscillator
- CNSP 48.87
- GLTO 10.91
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.